Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
deudomperidone
- Development stage
- Phase 2
- Lead developer
- CinDome Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Deudomperidone (CIN-102) is a novel, oral small molecule drug developed as a peripherally selective dopamine D2 and D3 receptor antagonist. It is a deuterated form of domperidone, engineered to improve pharmacokinetics and reduce cardiac liability compared to the non-deuterated parent compound. Deudomperidone acts as an antiemetic and prokinetic agent, improving gastric emptying and relieving symptoms such as nausea and vomiting associated with gastroparesis. The drug is being developed primarily for the treatment of gastroparesis, including diabetic gastroparesis. As of early 2025, it is in Phase 2 clinical trials for this indication in the United States[1][2][3][4][5][6][7].
- Other names
- deuterated domperidone
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on deudomperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on deudomperidone.